Literature DB >> 22718858

Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment.

Tangying Lu1, Dmitry I Gabrilovich.   

Abstract

Tumor-associated myeloid cells are the major type of inflammatory cells involved in the regulation of antitumor immune responses. One key characteristic of these cells is the generation of reactive oxygen (ROS) and reactive nitrogen species (RNS) in the tumor microenvironment. Recent studies have shown the important role of ROS and RNS, especially peroxynitrite, in immune suppression in cancer. ROS and RNS are involved in induction of antigen-specific T-cell tolerance, inhibition of T-cell migration to the tumor site, and tumor cell evasion of recognition by cytotoxic T cells. In preclinical settings, a number of potential therapeutic agents showed activity in blocking ROS/RNS in cancer and in improving the efficacy of cancer immune therapy. A better understanding of ROS/RNS-associated pathways in myeloid cells will help to identify more specific and direct targets to facilitate the development of more effective immune therapy for cancer. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718858      PMCID: PMC3445728          DOI: 10.1158/1078-0432.CCR-11-2939

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  56 in total

1.  Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.

Authors:  Je-In Youn; Michelle Collazo; Irina N Shalova; Subhra K Biswas; Dmitry I Gabrilovich
Journal:  J Leukoc Biol       Date:  2011-09-27       Impact factor: 4.962

2.  Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival.

Authors:  S Ekmekcioglu; J Ellerhorst; C M Smid; V G Prieto; M Munsell; A C Buzaid; E A Grimm
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

Review 3.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 4.  Coordinated regulation of myeloid cells by tumours.

Authors:  Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Vincenzo Bronte
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

5.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

Authors:  J Schmielau; O J Finn
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

Review 6.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

7.  Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.

Authors:  Torsten E Reichert; Laura Strauss; Eva M Wagner; William Gooding; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

8.  Cutting edge: MHC class II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response.

Authors:  H Chaim Birnboim; Anne-Marie Lemay; Debbie Ka Yee Lam; Rose Goldstein; John R Webb
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

9.  IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.

Authors:  Vincenzo Bronte; Paolo Serafini; Carmela De Santo; Ilaria Marigo; Valeria Tosello; Alessandra Mazzoni; David M Segal; Caroline Staib; Marianne Lowel; Gerd Sutter; Mario P Colombo; Paola Zanovello
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

10.  Immunotherapy earns its spot in the ranks of cancer therapy.

Authors:  Drew Pardoll; Charles Drake
Journal:  J Exp Med       Date:  2012-02-13       Impact factor: 14.307

View more
  45 in total

1.  Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.

Authors:  Amber Jin Giles; Caitlin Marie Reid; Justin DeWayne Evans; Meera Murgai; Yorleny Vicioso; Steven Lorenz Highfill; Miki Kasai; Linda Vahdat; Crystal Lee Mackall; David Lyden; Leonard Wexler; Rosandra Natasha Kaplan
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 12.701

Review 2.  Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target.

Authors:  Elizabeth A Grimm; Andrew G Sikora; Suhendan Ekmekcioglu
Journal:  Clin Cancer Res       Date:  2013-07-18       Impact factor: 12.531

3.  Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF-β.

Authors:  Jessica L Rastad; William R Green
Journal:  Virology       Date:  2016-09-12       Impact factor: 3.616

Review 4.  Multifaceted roles of PGE2 in inflammation and cancer.

Authors:  Masako Nakanishi; Daniel W Rosenberg
Journal:  Semin Immunopathol       Date:  2012-09-21       Impact factor: 9.623

Review 5.  Immunology Comes Full Circle in Melanoma While Specific Immunity Is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance.

Authors:  Elizabeth A Grimm
Journal:  Crit Rev Oncog       Date:  2016

6.  Monocyte glycolysis determines CD8+ T cell functionality in human Chagas disease.

Authors:  Liliana María Sanmarco; Natalia Eberhardt; Gastón Bergero; Luz Piedad Quebrada Palacio; Pamela Martino Adami; Laura Marina Visconti; Ángel Ramón Minguez; Yolanda Hernández-Vasquez; Eugenio Antonio Carrera Silva; Laura Morelli; Miriam Postan; Maria Pilar Aoki
Journal:  JCI Insight       Date:  2019-09-19

7.  Adoptive transfer of IFN-γ-induced M-MDSCs promotes immune tolerance to allografts through iNOS pathway.

Authors:  Fan Yang; Yang Li; Weilong Zou; Yanan Xu; Hao Wang; Wei Wang; Yong Zhao
Journal:  Inflamm Res       Date:  2019-05-04       Impact factor: 4.575

8.  Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.

Authors:  Susumu Fujiwara; Hiroshi Nagai; Noriko Shimoura; Shuntaro Oniki; Takayuki Yoshimoto; Chikako Nishigori
Journal:  J Invest Dermatol       Date:  2014-01-27       Impact factor: 8.551

9.  Priming of neutrophils toward NETosis promotes tumor growth.

Authors:  Mélanie Demers; Siu Ling Wong; Kimberly Martinod; Maureen Gallant; Jessica E Cabral; Yanming Wang; Denisa D Wagner
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 10.  Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

Authors:  Katherine H Parker; Daniel W Beury; Suzanne Ostrand-Rosenberg
Journal:  Adv Cancer Res       Date:  2015-05-12       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.